impetigo%20-and-%20ecthyma
IMPETIGO & ECTHYMA
Impetigo is a very contagious, superficial, bacterial skin infection that easily spreads among people in close contact.
Most cases occur in children and resolve spontaneously without scarring in approximately 14 days.
Ecthyma is a deeply ulcerated form of impetigo that extends to the dermis.
It has "punched-out" ulcers with yellow crust and elevated violaceous margins.
Most cases occur in children and elderly.
It may be a de novo infection or superinfection.

Impetigo%20-and-%20ecthyma Signs and Symptoms

Introduction

Impetigo (Nonbullous)

  • Most common form of impetigo
  • Also known as crusted impetigo or impetigo contagiosa
  • Most common in children 2-5 years of age

Impetigo (Bullous)

  • Newborns & younger children are commonly affected

Ecthyma

  • Typically occurs in children 6 months-18 years, in the elderly, immunocompromised [eg neutropenia, human immunodeficiency virus (HIV)], or patients w/ diabetes mellitus (DM) 

Definition

Impetigo

  • A very contagious, superficial, bacterial skin infection that easily spreads among people in close contact
  • Most cases occur in children & resolve spontaneously w/o scarring in approximately 14 days

Ecthyma

  • Deeply ulcerated form of impetigo that extends to the dermis
    • “Punched-out” ulcers w/ yellow crust & elevated violaceous margins

Etiology

Impetigo (Nonbullous)

  • S aureus & group A beta-hemolytic streptococci (GABS)

Imptetigo (Bullous)

  • Always caused by coagulase-positiveS aureus
    • A localized form of staphylococcal scalded skin syndrome

Ecthyma

  • Group A beta-hemolytic streptococci (Streptococcus pyogenes); S aureus is typically cultured from the lesions but is usually a secondary pathogen

Signs and Symptoms

Impetigo (Nonbullous)

  • Initially presents w/ macules or papules that quickly become small vesicles
    • Vesicles quickly pustulate & rupture leaving an erosion or clusters of erosion
    • Purulent discharge dries & forms honey-colored crusts
  • Usually asymptomatic though local adenopathy is common; pruritus or pain may occur occasionally
  • Lesions are typically found on exposed areas of the skin on the face (especially around the nose & mouth) & extremities
  • Carrier state: 4% of adults may be asymptomatic carrier

Impetigo (Bullous)

  • Newborns & younger children are commonly affected
  • Lesions (0.5-3 cm in diameter) typically develop on intact skin & begin as vesicles that turn into flaccid bullae that contain yellow serous fluid
    • Bullae rupture easily & a moist red-surfaced erosion appears surrounded by a thin rim of scale, which then forms a thin varnish-like light brown crust
  • Generally, there is no surrounding erythema but may have regional lymphadenopathy, pain or systemic symptoms
  • Lesions are often multiple, rapidly spread, & typically found on the face, buttocks, perineum & extremities,the trunk more frequently affected; in neonates, around the diaper area

Ecthyma

  • Lesions initially appear as pustules & vesicles that become ulcerated
    • Ulceration is frequently covered by adherent crusts
  • Associated w/ pain & lymphadenopathy; heals w/ scarring
  • Lesions are usually found on the legs

Risk Factors

Impetigo (Nonbullous)

  • Poor hygiene; warm climate; crowding; preceding skin breaks in the affected area from insect bites, wounds, viral infections (chicken pox, herpes simplex), scabies or burns; prior skin disease eg eczema, atopic dermatitis

Ecthyma

  • Insect bites, scabies, pediculosis, poor hygiene & malnutrition, heat & high humidity
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 20 Oct 2020

The increased risk of mortality among patients with cancer diagnosed with COVID-19 may be due to their older age and presence of comorbidities, according to a study presented at ECCVID 2020.

Pank Jit Sin, 02 Nov 2020
Application for Sputnik V, the tradename of the world’s first registered COVID-19 vaccine, has been submitted to the WHO for accelerated registration via the Emergency Use Listing (EUL) and prequalification.